S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:MESO

Mesoblast Stock Forecast, Price & News

$9.48
-0.03 (-0.32 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.32
Now: $9.48
$9.60
50-Day Range
$8.21
MA: $11.24
$16.99
52-Week Range
$3.12
Now: $9.48
$21.28
Volume329,214 shs
Average Volume1.81 million shs
Market Capitalization$1.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.71
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Mesoblast logo

MarketRank

Overall MarketRank

1.36 out of 5 stars

Medical Sector

601st out of 1,926 stocks

Biological Products, Except Diagnostic Industry

79th out of 177 stocks

Analyst Opinion: 3.1Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MESO
Previous SymbolOTCMKTS:MBLTY
CUSIPN/A
CIKN/A
Phone61-3-9639-6036
Employees102

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.16 million
Book Value$4.70 per share

Profitability

Net Income$-77,940,000.00
Net Margins-591.00%

Miscellaneous

Market Cap$1.11 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$9.48
-0.03 (-0.32 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mesoblast (NASDAQ:MESO) Frequently Asked Questions

How has Mesoblast's stock price been impacted by Coronavirus?

Mesoblast's stock was trading at $6.0250 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MESO stock has increased by 57.3% and is now trading at $9.48.
View which stocks have been most impacted by COVID-19
.

Is Mesoblast a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Mesoblast stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View analyst ratings for Mesoblast
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Mesoblast?

Wall Street analysts have given Mesoblast a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mesoblast wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Mesoblast's CEO?

1,448 employees have rated Mesoblast CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Mesoblast's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Mesoblast
.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) issued its earnings results on Thursday, November, 19th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.17. The firm earned $1.31 million during the quarter, compared to analyst estimates of $119.03 million. Mesoblast had a negative net margin of 591.00% and a negative return on equity of 18.69%.
View Mesoblast's earnings history
.

What price target have analysts set for MESO?

6 brokerages have issued twelve-month target prices for Mesoblast's shares. Their forecasts range from $7.50 to $20.00. On average, they expect Mesoblast's stock price to reach $14.55 in the next year. This suggests a possible upside of 53.5% from the stock's current price.
View analysts' price targets for Mesoblast
or view Wall Street analyst' top-rated stocks.

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 64)
  • Mr. Josh Muntner BFA, M.B.A., Chief Financial Officer (Age 52)
  • Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec. (Age 53)
  • Mr. Michael Schuster M.B.A., MS, BSc, MBA, Head of Pharma Partnering (Age 44)
  • Dr. Eric Strati M.B.A., Ph.D., Pharm.D., MBA, Sr. VP of Commercial
  • Dr. Fred Grossman, Chief Medical Officer
  • Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S., Chief Operating Officer (Age 57)
  • Sir Jonathan Richard Symonds B.A., F.C.A., CBE, BA, FCA, Head of Corp. Fin. & Strategy (Age 62)
  • Ms. Julie Meldrum, Global Head of Corp. Communications
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.06%) and Game Plan Financial Advisors LLC (0.01%).

Which major investors are buying Mesoblast stock?

MESO stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, and Game Plan Financial Advisors LLC.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $9.48.

How big of a company is Mesoblast?

Mesoblast has a market capitalization of $1.11 billion and generates $32.16 million in revenue each year. The company earns $-77,940,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Mesoblast employs 102 workers across the globe.

What is Mesoblast's official website?

The official website for Mesoblast is www.mesoblast.com.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.